T-cell Acute Lymphoblastic Leukemia

• FDA approval · 2012-02-06
  FDA Approved: ARRANON — Supplemental Application (Sandoz Inc)

  FDA approves a supplemental application for ARRANON (nelarabine) submitted by Sandoz Inc.

• CLINICAL_TRIALS withdrawal · 2012-01-23
  Clinical Trial Update: Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens [Phase 2]

  A Phase 2 study of forodesine hydrochloride in relapsed/refractory precursor T-lymphoblastic leukemia/lymphoma was terminated; no efficacy r…

• FDA approval · 2009-12-15
  FDA Approved: ARRANON — Supplemental Application (Sandoz Inc)

  FDA approved a supplemental application for ARRANON (nelarabine) from Sandoz Inc. This action concerns the supplemental NDA submitted by San…